Multiple Myeloma & Plasma Cell Disorders

Overview & Definition

Multiple Myeloma is a blood cancer originating from malignant plasma cells—the antibody-producing white blood cells inside the bone marrow. Uncontrolled proliferation of abnormal plasma cells crowding out healthy blood cells and producing excess monoclonal paraprotein (M-protein or light chains) leads to bone destruction, kidney impairment, anemia, and recurrent infections.

Types & Spectrum of Plasma Cell Disorders

Monoclonal Gammopathy of Undetermined Significance (MGUS): A asymptomatic precursor condition requiring routine clinical surveillance without immediate chemotherapy.
Smoldering Multiple Myeloma (SMM): An intermediate stage characterized by higher M-protein or marrow plasma cells (>10% to 60%) without end-organ damage; risk-stratified to guide early targeted intervention.
Active / Symptomatic Multiple Myeloma: Diagnosed when clonal bone marrow plasma cells exceed 10% (or biopsy-proven plasmacytoma) accompanied by CRAB criteria or specific myeloma-defining biomarkers.
Solitary Plasmacytoma: A localized single lesion of abnormal plasma cells in bone or soft tissue treated with definitive radiation therapy and close monitoring.

Common Symptoms & Warning Signs (CRAB Criteria)

Clinical manifestations of Multiple Myeloma are classically grouped under the CRAB criteria and specific biomarkers:

⚠️ C – Calcium Elevation: Hypercalcemia causing excessive thirst, frequent urination, nausea, constipation, or confusion.

⚠️ R – Renal Impairment: Kidney insufficiency or elevated creatinine due to light chain deposition in renal tubules.

⚠️ A – Anemia: Low hemoglobin causing persistent fatigue, weakness, dizziness, and shortness of breath.

⚠️ B – Bone Lesions: Lytic bone lesions, severe bone pain (especially back or ribs), and pathological fractures.

⚠️ Recurrent Infections: Frequent bacterial pneumonia or urinary tract infections due to impaired normal antibody production.

Comprehensive Diagnostic Evaluation

Accurate diagnosis and risk stratification at Sunrise Hematology follow International Myeloma Working Group (IMWG) guidelines:

Blood & Urine Paraprotein Testing: Serum Protein Electrophoresis (SPEP), Immunofixation (IFE), Urine Protein Electrophoresis (UPEP), and Serum Free Light Chain (FLC) kappa/lambda ratio analysis.
Bone Marrow Aspirate & Biopsy: Quantifying plasma cell percentage, flow cytometry immunophenotyping (CD138, CD56), and FISH cytogenetics to identify high-risk abnormalities [del(17p), t(4;14), t(14;16), gain(1q)].
Advanced Skeletal & Body Imaging: Low-dose whole-body CT (WBCT), MRI, or 18F-FDG PET-CT to evaluate lytic bone disease and extramedullary lesions.
Organ Function & Staging Markers: Serum beta-2 microglobulin, LDH, albumin, serum calcium, and renal panel for R-ISS / R2-ISS staging.

Evidence-Based Treatment Options

Modern myeloma therapy has revolutionized patient survival through targeted triplets, quadruplets, and autologous stem cell transplantation:

Induction Targeted Combination Therapy: Multi-drug quadruplets such as Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (Dara-VRd) or VRd to achieve deep molecular remissions.
Autologous Stem Cell Transplant (ASCT): High-dose Melphalan chemotherapy followed by rescue with the patient's own harvested peripheral blood stem cells for eligible patients.
Novel Monoclonal Antibodies & Immunotherapy: Anti-CD38 monoclonal antibodies (Daratumumab, Isatuximab) and immunomodulatory agents (Lenalidomide, Pomalidomide) designed to selectively target plasma cells and stimulate host immunity.
Proteasome Inhibitors: Bortezomib, Carfilzomib, and Ixazomib to disrupt intracellular protein degradation pathways in malignant plasma cells.
Bone Preservation & Supportive Care: Monthly bisphosphonates (Zoledronic Acid) or Denosumab to heal lytic bone lesions, prevent fractures, and normalize serum calcium levels.
BCMA-Targeted CAR-T Cell Therapy: Advanced cellular immunotherapy option for relapsed or refractory disease targeting B-cell maturation antigen (BCMA).

Frequently Asked Questions

MGUS is a benign precursor with low M-protein (<3 g/dL) and <10% marrow plasma cells without symptoms. Smoldering Myeloma has higher M-protein or 10–60% plasma cells but no CRAB symptoms. Active Myeloma involves organ damage (CRAB criteria) or myeloma-defining biomarkers and requires immediate treatment.

Autologous stem cell transplantation (ASCT) remains the standard-of-care consolidation for transplant-eligible patients following initial induction therapy, significantly extending progression-free survival. For transplant-ineligible patients, continuous modern combination regimens offer excellent disease control.

Bone pain is managed through rapid myeloma cytoreduction, bone-strengthening bisphosphonates, and localized radiotherapy if needed. Kidney function often improves markedly with prompt anti-myeloma therapy, hydration, and avoiding nephrotoxic medications.